Lantheus Holdings Inc (LNTH)

Lantheus Holdings' stock price has been influenced by several events. Lantheus reported its second-quarter 2025 financial results and announced FDA acceptance of an NDA for a new formulation of its piflufolastat F 18 PSMA PET imaging agent. They also closed the acquisition of Life Molecular Imaging. Lantheus participated in the Morgan Stanley 23rd Annual Global Healthcare Conference. Lantheus reported its third-quarter 2025 financial results. Lantheus announced plans to present Florbetaben F 18 data at CTAD 2025. An article highlighted a shrinking margins and a shifting product mix. Lantheus announced the closing of its SPECT Business Sale to SHINE Technologies. An analyst report downgraded Lantheus, citing concerns about management and competition. Lantheus' Q4 2025 earnings are estimated to be reported.

Specific detailed demand seasonality for Lantheus Holdings' individual products is not explicitly provided. The demand for imaging services is generally growing due to the increasing prevalence of chronic diseases and technological advancements. Radiology services experience the highest volume on weekdays during normal business hours. There may be daily or weekly fluctuations in the utilization of diagnostic imaging services that could indirectly influence demand. No explicit seasonal patterns on a quarterly or yearly basis for Lantheus's specific products were found.

Lantheus Holdings, Inc. is a global life sciences company focused on developing, manufacturing, and commercializing diagnostic imaging agents and nuclear medicine products. The company provides solutions for detecting and managing cardiovascular and oncologic diseases. Lantheus operates in the Health Technology sector, specifically in the Medical Specialties and Pharmaceutical Products industries. Lantheus's major products include DEFINITY, TechneLite, Xenon-133, Neurolite, Cardiolite, PYLARIFY, Automated Bone Scan Index, RELISTOR, aPROMISE, PYLARIFY AI, and Flurpiridaz.

Lantheus operates in the U.S. and internationally. In the U.S., it directly produces and markets its products. Internationally, it has direct distribution in Canada and Puerto Rico and third-party distribution relationships across Europe, Canada, Australia, Asia-Pacific, Central America, South America, and Latin America. The company has offices in Massachusetts, New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom.

Lantheus has maintained a "Moderate Buy" consensus rating from analysts. However, the company has faced challenges including a decline in revenue from its Pylarify product, an earnings decline, and concerns about management and competition. Despite these challenges, Lantheus is actively working to reinforce PYLARIFY's clinical differentiation and support its PSMA PET franchise and is expanding its portfolio and pipeline.

Lantheus Holdings, Inc. has significant institutional ownership, with 99.06% of the stock held by institutions including BlackRock, Inc., Vanguard Group Inc, Janus Henderson Group Plc, Fmr Llc, Morgan Stanley, Farallon Capital Management Llc, and State Street Corp. Key individual insider owners include Sriram Venkataraman, Avista Capital Partners GP LLC, David F. Burgstahler, and Rajiv A. Patel. Insiders have shown net selling activity in the last 12 and 3 months.